NOVEL COMPOUNDS
    2.
    发明申请

    公开(公告)号:US20220064169A1

    公开(公告)日:2022-03-03

    申请号:US17288225

    申请日:2019-10-23

    Abstract: The present disclosure relates to novel PDE2 inhibitory compounds of Formula I as described herein, their use as pharmaceuticals and pharmaceutical compositions comprising them.

    COMPOUNDS AND METHODS
    6.
    发明申请

    公开(公告)号:US20170291904A1

    公开(公告)日:2017-10-12

    申请号:US15512005

    申请日:2015-09-17

    CPC classification number: C07D487/14

    Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.

    ORGANIC COMPOUNDS
    10.
    发明申请
    ORGANIC COMPOUNDS 审中-公开
    有机化合物

    公开(公告)号:US20150072965A1

    公开(公告)日:2015-03-12

    申请号:US14539859

    申请日:2014-11-12

    Abstract: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.

    Abstract translation: 任选取代的4,5,7,8-四氢 - (任选4-氧代,4-硫代或4-亚氨基)-2H-咪唑并[1,2-a]吡咯并[3,4-e]嘧啶或4,5 ,7,8,9-五氢 - (任选4-氧代,4-硫代或4-亚氨基)-2H-嘧啶并[1,2-a]吡咯并[3,4-e]嘧啶化合物或式 ),其生产方法,它们作为药物的用途和包含其的药物组合物。

Patent Agency Ranking